Saturday, December 9, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Professor of Translational Rheumatology
King's College London
Consultant Rheumatologist
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Associate Professor of Medicine
Director
Penn Psoriatic Arthritis Clinic and Penn Center for Clinical Epidemiology and Biostatistics
Perelman School of Medicine
Philadelphia, Pennsylvania, United States
Department of Gastroenterology, Infectiology, and Rheumatology
Charité University Hospital
Berlin, Germany
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.75 ABIM MOC points
This educational activity is intended for an international audience of rheumatologists, dermatologists, and primary care physicians.
The goal of this activity is for learners to be better able to discuss key clinical data on emerging therapies for spondyloarthritis and the potential for these novel agents to improve outcomes for patients in clinical practice.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Professor of Translational Rheumatology
King's College London
Consultant Rheumatologist
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Associate Professor of Medicine
Director
Penn Psoriatic Arthritis Clinic and Penn Center for Clinical Epidemiology and Biostatistics
Perelman School of Medicine
Philadelphia, Pennsylvania, United States
Department of Gastroenterology, Infectiology, and Rheumatology
Charité University Hospital
Berlin, Germany
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 3/9/2023
Valid for credit through: 3/9/2024, 11:59 PM EST
processing....
Este comentario es parte de una actividad educativa más extensa. Después de participar, vuelva a Optimizing Outcomes for Spondyloarthritis: Focus on Interleukin-23/-17 Inhibitors para acceder a todo el contenido educativo relacionado.
| « Return to: Optimizing Outcomes for Spondyloarthritis: Focus on Interleukin-23/-17 Inhibitors |
